ANKTIVA®
BCG
Clinical Trials
Find a Trial
Become a Trial
Investigator
License our Cells
Science
Platforms
Pipeline
Expanded Access
Research
Approach
Patients
Trial Investigators
Researchers
Condition
Bladder Cancer
Glioblastoma
HIV
Lynch / Colon Cancer
Non-Hodgkin Lymphoma
Human Papillomavirus
Non-Small Cell Lung Cancer
Company
About Us
Investors
News and Events
Contact
Careers
Founder’s Vision
Cancer Moonshot 2020
Childhood Cancer – Sen. McCain
Cancer Moonshot Announcement
Formation of ImmunityBio
Select Page
Acute Myeloid Leukemia
Mar 19, 2024
Planned – Platinum-Resistant Ovarian Cancer
Mar 19, 2024
Locally Advanced or Metastatic Solid Tumors
May 10, 2023
Search for:
Recent Posts
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
AUA 2025
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ